New eye drops aim to soothe dry eyes with fewer doses
NCT ID NCT07422259
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested whether Reinnerva/Lubristil+G eye drops work better than Vismed for people with dry eyes. Forty adults with dry eye symptoms used one drop in each eye twice daily (Reinnerva/Lubristil+G) or four times daily (Vismed) for 60 days. Researchers measured tear production, tear film stability, and symptom scores to see which drop provided more relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Reinnerva/Lubristil+G sterile eye drops (artificial tears)
- What this could lead to
- If successful, this could offer a more convenient option for relieving dry eye symptoms with fewer daily applications.
- What could go wrong
- This is a small, completed post-market study with only 40 participants, so results may not apply to everyone. It compares two artificial tears, not a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Signed informed consent * Male and female, aged 18 to 80 years * Alteration of the tear film or bilateral ocular surface discomfort resulting from one of the following conditions: Patients receiving chronic therapy with antihypertensive eye drops; Patients receiving post-ocular surgery therapy for at least 15 days * At least two of the following symptoms of dry eye: burning, stinging, dry eye sensation, foreign body sensation, photophobia * At least two of the following: Schirmer's test (8 mm lower in 5 minutes) BUT (Burning Time) less than 10 seconds Fluorescein Infection Infection (NEI) score ≥3 Exclusion Criteria: * Active keratitis caused by herpes simplex, vaccinia virus, varicella-zoster, and other viral infections of the cornea and conjunctiva * Current bacterial, fungal, and tuberculosis infections * Corneal stromal perforations and ulcers * Hypersensitivity to any of the product components * Current ocular allergy or allergic rhinitis * Participation in a clinical trial in the month prior to the start of the study * Systemic anti-acne therapy in the 6 months prior to the start of the study * Any change in systemic therapy in the month prior to the start of the study * Contact lens use in the week prior to the start of the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Keratoconjunctivitis sicca are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UOC of Ophthalmology, AOU Policlinico "G. Martino"
Messina, 98125, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.